MNK News and Press, Mallinckrodt plc From 01/22/23

Mallinckrodt Presents New TERLIVAZ® (terlipressin) for Injection Data on Hepatorenal Syndrome (HRS) Reversal at the Society of Critical Care Medicine (SCCM) 2023 Critical Care Congress PR Newswire – Findings from a retrospective analysis suggest that patients with ba...

NEW YORK, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) announced today that it will release results for its fourth quarter ended December 31, 2022, on Thursday, February 2, 2023, after the market close. The Company w...

Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer PR Newswire DUBLIN , Jan. 12, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical c...

Summary Mallinckrodt develops and markets specialty pharmaceutical products for autoimmune and rare diseases. In my view, investors really forgot about the potential future free cash flow that Mallinckrodt could generate. Even considering the lawsuits, I believe that the stock...

Mallinckrodt plc (MNK) Q3 2022 Earnings Conference Call November 8, 2022, 08:30 AM ET Company Participants Daniel Speciale - Global Corporate Controller & Chief IR Officer Sigurdur Olafsson - President & CEO Bryan Reasons - CFO Conference Call Parti...

Mallinckrodt press release ( NYSE: MNK ): Q3 Net loss of $348.6M Revenue of $465.4M (-8.2% Y/Y). Adjusted EBITDA  was $166.1 Mallinckrodt's cash balance at the end of the third quarter was $391.2 million, and the Company continues to maintain an undrawn $200...

Mallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms Guidance PR Newswire Launched Terlivaz ® Following U.S. Food and Drug Administration (FDA) Approval in September; Submitted U.S. FDA Premarket Notification Application for Next-Generat...

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting PR Newswire – Seven scientific abstracts spanning c...

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2022 Scientific Meeting PR Newswire – Three scientific abstracts highlighting clin...

Mallinckrodt ( NYSE: MNK ) has gained approval to list its ordinary shares on NYSE American. The ordinary shares of the specialty pharmaceutical company are expected to commence trading on NYSE American under the ticker symbol "MNK" from October 27, 2022. Trading on the OT...